Navigation Links
New Treatment Destroys Kidney Tumors Without Side Effects
Date:7/14/2011

SARASOTA, Fla., July 14, 2011 /PRNewswire/ -- Elliot Hatton was on a cruise celebrating his 25th wedding anniversary when he noticed blood in his urine.  He mentioned it to his wife, but since it didn't happen again, he ignored it.  Two months later, his urine turned rust colored, and the veins around his testicles were swollen.  His physician ordered tests, and Elliot was one of the 61,000 Americans diagnosed with kidney cancer annually.  And according to TMD Limited, a medical tourism company, Hatton joined an even larger group  - he became one of half a million US citizens who go out of the country each year for medical treatment.

At 55, Hatton had several risk factors: he was a smoker, overweight and  had high blood pressure.  Other risk factors include a family history of kidney cancer and the Von-Hipbel-Lindau (VHL) Syndrome, a hereditary disease affecting the VHL gene.  Men are diagnosed with kidney cancer twice as often as women, usually after age 50.

In addition to bloody urine, other symptoms include anemia, pain or a lump or mass in the side, back or abdomen, unexplained weight loss, fever and persistent exhaustion.  In some cases there are no symptoms.

Kidneys are the size of a fist.  Urine collects in the hollow space in the middle of each kidney, then passes from the pelvis into the bladder through a long tube called the ureter, then leaves the body through a short tube called the urethra.  Kidneys also make substances to help control blood pressure and to make red blood cells.

When normal cell growth goes awry, and damaged cells don't die off the way they should, the buildup of extra cells form a tumor.  In renal cell carcinoma (kidney cancer), tumors can form is the very small tubes in the kidney that filter blood and remove waste products, or in the center of the kidney, where urine collects.  Pieces of the tumors can break off and spread through the lymp
'/>"/>

SOURCE TMD Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
5. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
6. With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients
7. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
8. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
9. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
10. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
11. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... (Nasdaq: BCRX ) today announced that it ... Industry conference in New,York. A live webcast of ... 2:00 p.m. Eastern Time may be accessed at ... be archived for seven days. (Logo: ...
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) today announced ... at the 2007 UBS Global Life Sciences,Conference which ... York on Wednesday,September 26 at 1:30 p.m. EDT. ... webcast of the presentation will be accessible through ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... Research in Oral Biology Award will be presented to ... at the International Association for Dental Research (IADR) 87th ... 1, 2009. , Dr. McCulloch has been professor in ... He also serves as Director of,the Canadian Institutes of ...
... medulloblastoma, the most frequent malignant brain tumor in childhood, ... spread and what the chances of disease relapse are. ... at the Heidelberg University Hospital and the German Cancer ... set of tumor markers, the intensity of treatment can ...
... American Association for Cancer Research extends its sincere ... to lead the Food and Drug Administration (FDA). ... advancement of cutting-edge products and therapies that are ... Her leadership will bring new perspectives to important ...
Cached Biology News:New tumor markers determine therapy intensity 2New tumor markers determine therapy intensity 3
...
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: